HOME > About Us > History
2017
   10  VM202's generic name which is 'donaperminogene seltoplasmid' approved by INN and USAN
   10  Phase III clinical study of VM202-PAD (Critical Limb Ischemia) approved by CFDA
   07  2nd Phase III clinical study of VM202-DPN (Diabetic Peripheral Neuropathy) approved by US FDA
2016
   09  Phase II clinical study of VM202-ALS (Amyotrophic Lateral Sclerosis) approved by US FDA.
   08  Phase II clinical study of VM202-CAD (Ischemic Heart Disease) approved by Korea FDA.
   05  Fast Track designation by US FDA for VM202-ALS
2015
   12  Licensing agreement for novel antibodies to develop CAR-T (chimeric antigen receptor T cell) therapy with bluebird bio,          Inc. in the USA.
   08  Phase III clinical study of VM202-PAD (Peripheral Artery Disease) approved by US FDA.
   04  1st Phase III clinical study of VM202-DPN (Diabetic Peripheral Neuropathy) approved by US FDA.
2014
   11  Phase II clinical study of VM202-DPN (Diabetic Peripheral Neuropathy) completed in the USA and Korea.
   04  Phase II clinical study of VM202-PAD (Critical Limb Ischemia) completed in the USA and Korea.
   02  Orphan drug designation by US FDA for Amyotrophic Lateral Sclerosis (VM202-ALS).
   02  Domestic launch of health functional food based on HX106 & red ginseng, designed to improve working memory.
2013
   11  Collaborative development agreement for Amyotrophic Lateral Sclerosis (VM202-ALS) with Reyon Pharmaceutical
         Co.,Ltd. in Korea.
   12  Phase I clinical study of VM206RY completed in Korea.
   10  Phase I/II clinical study of VM202-ALS (Amyotrophic Lateral Sclerosis medicine) approved by US FDA.
2012
   11  Murphin (health functional food) launched in Korea.
   11  Osteoarthritis medicine PG201 launched in Korea.
   07  Chronic Hepatitis B (HBV) vaccine licensed out to Reyon Pharmaceutical.
   03  Phase II clinical study of VM202-DPN (Diabetic Peripheral Neuropathy medicine) approved by KFDA.
   03  Phase III clinical study of VM501 (Chemotherapy-Induced Thrombocytopenia medicine) approved by CFDA.
   03  NDA approval of PG201 (osteoarthritis medicine), the 7th botanical medicine to be approved in Korea.
2011
   11  Phase II clinical study of VM202-DPN (Diabetic Peripheral Neuropathy medicine) approved by US FDA.
   09  Phase II clinical study of VM202-PAD (Peripheral Artery Disease medicine) approved by CFDA.
   07  US operation named VM BioPharma.
   02  Phase I clinical study of VM206RY (Anti-Cancer Therapeutic Vaccine) approved by KFDA.
   02  Signed out-licensing deal with Enlyton Ltd. on 3EB antibody cancer diagnostic technology.
   01  Allex-I™ (liquid form of Allex) launched.
2010
   10  Phase II clinical study of VM202-PAD (Peripheral Artery Disease medicine) approved by KFDA.
2009
   11  Domestic launch of Allex, a nutraceutical designed to improve immune hypersensitivity and AtoLatte, a topical
         solution for atopic dermatitis.
   09  Acquisition of Helixir, a developer of botanical drugs and nutraceuticals.
   07  US FDA approval of Phase II clinical trial for peripheral artery disease (VM202-PAD).
   03  US FDA approval of collaborative Phase I/II clinical trial for coronary artery disease (VM202-CAD).
   03  US FDA approval of Phase I/II clinical trial for diabetic peripheral neuropathy (VM202-DPN).
2008
   06  Chinese State Food and Drug Administration (SFDA) approval of Phase I clinical trial for peripheral artery disease
         (VM202-PAD).
   01  Licensing agreement for Anti-cancer therapeutic vaccine (VM206) with Reyon Pharmaceutical Co., Ltd. in Korea.
2006
   11  Acquired approval for a clinical trial for critical limb ischemia (VM202-PAD) from US FDA, the first biomedicine
         case by Korean company.
   10  Korea FDA approval of Phase I clinical trial for VM202-CAD (Coronary Artery Disease).
2005
   12  IPO-KOSDAQ, Korean stock exchange.
2004
   06  Licensing agreement for Cardiovascular therpeutics(VM202) with Beijing Northland Biotech in China.
   01  Licensing agreement for Cardiovascular therpeutics(VM202) with Reyon Pharmaceutical Co., Ltd. in Korea.
2003
   06  Signing of a joint research and development agreement with France's Genethon III in France.
2001
   02  Acquired a clinical trial approval for gene therapy from KFDA, the first biomedicine case for Ischemic Limb Disease
         in Korea.
2000
   03  Investment of USD 6 million by Takara Shuzo, Japan (now Takara Bio Inc.), along with the rights
         to use Takara’s patents.
1999
   09  Established Joint Venture called ‘Virotech’ with Oxford Biomedica.
1996
   11  Incorporation of ViroMedica Pacific, Inc. (now ViroMed Co., Ltd.)